{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:20:54Z","timestamp":1788801654769,"version":"build-2803163510"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian Society for Antimicrobial"},{"name":"Australian National Health and Medical Research Council","award":["APP1117065"],"award-info":[{"award-number":["APP1117065"]}]},{"name":"Australian"},{"name":"for a Centre of Research Excellence","award":["APP2007007"],"award-info":[{"award-number":["APP2007007"]}]},{"name":"Investigator Grant","award":["APP2009736"],"award-info":[{"award-number":["APP2009736"]}]},{"name":"Advancing Queensland Clinical Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Catheter-associated urinary tract infections (CA-UTIs) are a common hospital-acquired infection. We examined ciprofloxacin activity in a novel CA-UTI in vitro model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Three ATCC strains [Escherichia coli (ECO)-25922, Klebsiella pneumoniae (KPN)-700721, Pseudomonas aeruginosa (PAE)-27853] and 45 clinical urinary isolates were assessed. Biofilm mass and planktonic bacterial density were quantified during drug-free incubation (72\u2005h) and following ciprofloxacin exposure (equivalent 750\u2005mg orally q12h, 3\u2005days).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>ECO produced smaller biofilms (6.3\u200a\u00b1\u200a1.1\u2005log10\u2005cfu\/cm2) compared with KPN (7.1\u200a\u00b1\u200a0.7\u2005log10\u2005cfu\/cm2) and PAE (7.0\u200a\u00b1\u200a1.2\u2005log10\u2005cfu\/cm2), which extended along the entire catheter length. Following ciprofloxacin, all isolates with MIC\u200a&amp;gt;\u200a4\u2005mg\/L had minimal biofilm disruption or planktonic kill. Ciprofloxacin resistance was most common in PAE isolates (10\/16 isolates), compared with ECO (3\/16 isolates) and KPN (6\/16 isolates). Greater ciprofloxacin exposure (AUC0\u201324\/MIC) was required for a 3\u2005log10 biofilm kill for KPN (5858; R2\u2005=\u20050.7774) compared with ECO (2117; R2\u2005=\u20050.7907) and PAE (2485; R2\u2005=\u20050.8260). Due to persistent growth in the bladder, ECO required greater ciprofloxacin exposure for a 3\u2005log10 planktonic kill (5920; R2\u2005=\u20050.8440) compared with KPN (2825; R2\u2005=\u20050.9121) and PAE (1760; R2\u2005=\u20050.8781). Monte Carlo simulation supported a 95% PTA for both a 3\u2005log10 biofilm and planktonic kill for ECO and KPN isolates with MIC\u200a\u2264\u200a0.5\u2005mg\/L and PAE isolates with MIC\u200a\u2264\u200a1\u2005mg\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In a novel CA-UTI model, following simulated ciprofloxacin therapy, KPN biofilms were comparatively more difficult to disrupt, ECO planktonic growth frequently persisted in the bladder, and PAE had greater propensity for emergence of ciprofloxacin resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae424","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T21:06:46Z","timestamp":1733260006000},"page":"413-426","source":"Crossref","is-referenced-by-count":4,"title":["Oral ciprofloxacin biofilm activity in a catheter-associated urinary tract infection model"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6590-6127","authenticated-orcid":false,"given":"Iain J","family":"Abbott","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Alfred Hospital and School of Translational Medicine, Monash University , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor R B","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Alfred Hospital and School of Translational Medicine, Monash University , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"van Gorp","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Alfred Hospital and School of Translational Medicine, Monash University , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-9854","authenticated-orcid":false,"given":"Steve C","family":"Wallis","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A","family":"Roberts","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8869-1509","authenticated-orcid":false,"given":"Joseph","family":"Meletiadis","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens , Haidari, Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-2126","authenticated-orcid":false,"given":"Anton Y","family":"Peleg","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Alfred Hospital and School of Translational Medicine, Monash University , Melbourne, Victoria ,","place":["Australia"]},{"name":"Department of Microbiology, Infection Program, Monash Biomedicine Discovery Institute, Monash University , Clayton, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"2025020223513567300_dkae424-B1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41467-023-44095-0","article-title":"Microbial co-occurrences on catheters from long-term catheterized patients","volume":"15","author":"Nye","year":"2024","journal-title":"Nat Commun"},{"key":"2025020223513567300_dkae424-B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jhin.2023.03.020","article-title":"Pragmatic review of interventions to prevent catheter-associated urinary tract infections (CAUTIs) in adult inpatients","volume":"136","author":"Gray","year":"2023","journal-title":"J Hosp Infect"},{"key":"2025020223513567300_dkae424-B3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1086\/650482","article-title":"Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America","volume":"50","author":"Hooton","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2025020223513567300_dkae424-B4","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1093\/cid\/cir257","article-title":"Guidelines for the prevention of intravascular catheter-related infections","volume":"52","author":"O'Grady","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025020223513567300_dkae424-B5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jhin.2016.01.012","article-title":"Length of stay and mortality associated with healthcare-associated urinary tract infections: a multi-state model","volume":"93","author":"Mitchell","year":"2016","journal-title":"J Hosp Infect"},{"key":"2025020223513567300_dkae424-B6","author":"Australian Commission on Safety and Quality in Health Care"},{"key":"2025020223513567300_dkae424-B7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.idh.2017.07.001","article-title":"The burden of healthcare-associated infection in Australian hospitals: a systematic review of the literature","volume":"22","author":"Mitchell","year":"2017","journal-title":"Infect Dis Health"},{"key":"2025020223513567300_dkae424-B8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41579-020-0324-0","article-title":"Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies","volume":"18","author":"Klein","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"2025020223513567300_dkae424-B9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41579-022-00682-4","article-title":"Tolerance and resistance of microbial biofilms","volume":"20","author":"Ciofu","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"2025020223513567300_dkae424-B10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1128\/MMBR.00013-14","article-title":"Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics","volume":"78","author":"Lebeaux","year":"2014","journal-title":"Microbiol Mol Biol Rev"},{"key":"2025020223513567300_dkae424-B11","doi-asserted-by":"publisher","first-page":"2986742","DOI":"10.1155\/2018\/2986742","article-title":"Review of catheter-associated urinary tract infections and in vitro urinary tract models","volume":"2018","author":"Cortese","year":"2018","journal-title":"J Healthc Eng"},{"key":"2025020223513567300_dkae424-B12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.mimet.2016.06.013","article-title":"Evaluation of the in vitro growth of urinary tract infection-causing gram-negative and gram-positive bacteria in a proposed synthetic human urine (SHU) medium","volume":"127","author":"Ipe","year":"2016","journal-title":"J Microbiol Methods"},{"key":"2025020223513567300_dkae424-B13","author":"International Organisation for Standardization"},{"key":"2025020223513567300_dkae424-B14","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025020223513567300_dkae424-B15","author":"The European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025020223513567300_dkae424-B16","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/jac\/dkac045","article-title":"Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model","volume":"77","author":"Abbott","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025020223513567300_dkae424-B17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/jac\/dkac402","article-title":"Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model","volume":"78","author":"Abbott","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025020223513567300_dkae424-B18","author":"US Food and Drug Administration"},{"key":"2025020223513567300_dkae424-B19","author":"EUCAST"},{"key":"2025020223513567300_dkae424-B20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/14787210.2020.1813567","article-title":"Antimicrobial pharmacokinetics and preclinical in vitro models to support optimized treatment approaches for uncomplicated lower urinary tract infections","volume":"19","author":"Abbott","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025020223513567300_dkae424-B21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ijantimicag.2006.07.026","article-title":"Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose","volume":"28","author":"Wagenlehner","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"2025020223513567300_dkae424-B22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1128\/AAC.43.3.525","article-title":"Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin","volume":"43","author":"Kamberi","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223513567300_dkae424-B23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000061402","volume-title":"Urinary Tract Infections. Infectiology","author":"Naber","year":"1997"},{"key":"2025020223513567300_dkae424-B24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.resmic.2011.01.004","article-title":"Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine","volume":"162","author":"Erdogan-Yildirim","year":"2011","journal-title":"Res Microbiol"},{"key":"2025020223513567300_dkae424-B25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000342423","article-title":"Impact of pH on activity of trimethoprim, fosfomycin, amikacin, colistin and ertapenem in human urine","volume":"90","author":"Burian","year":"2012","journal-title":"Pharmacology"},{"key":"2025020223513567300_dkae424-B26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/jac\/dkz488","article-title":"Low pH reduces the activity of ceftolozane\/tazobactam in human urine, but confirms current breakpoints for urinary tract infections","volume":"75","author":"Nussbaumer-Pr\u00f6ll","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025020223513567300_dkae424-B27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/jac\/dkad361","article-title":"Impact of pH on the activity of novel cephalosporin cefiderocol in human urine","volume":"79","author":"Nussbaumer-Pr\u00f6ll","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025020223513567300_dkae424-B28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/antibiotics13020116","article-title":"Acidic urine pH and clinical outcome of lower urinary tract infection in kidney transplant recipients treated with ciprofloxacin and fosfomycin","volume":"13","author":"Herrera-Espejo","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2025020223513567300_dkae424-B29","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1093\/jac\/dkx313","article-title":"Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections","volume":"72","author":"Fransen","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025020223513567300_dkae424-B30","doi-asserted-by":"publisher","first-page":"e02498-16","DOI":"10.1128\/AAC.02498-16","article-title":"Pharmacodynamic evaluation of fosfomycin against Escherichia coli and Klebsiella spp. from urinary tract infections and the influence of pH on fosfomycin activities","volume":"61","author":"Fedrigo","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223513567300_dkae424-B31","doi-asserted-by":"publisher","first-page":"e01804-20","DOI":"10.1128\/AAC.01804-20","article-title":"Ciprofloxacin pharmacokinetics\/pharmacodynamics against susceptible and low-level resistant Escherichia coli isolates in an experimental ascending urinary tract infection model in mice","volume":"65","author":"Jakobsen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223513567300_dkae424-B32","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.1128\/AAC.01489-13","article-title":"Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6\u2032)-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro","volume":"57","author":"Guillard","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223513567300_dkae424-B33","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1093\/jac\/dks224","article-title":"Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model","volume":"67","author":"Jakobsen","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2025020223513567300_dkae424-B34","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1128\/AAC.01664-08","article-title":"Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection","volume":"53","author":"Allou","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223513567300_dkae424-B35","doi-asserted-by":"publisher","first-page":"691210","DOI":"10.3389\/fcimb.2021.691210","article-title":"Recurrent urinary tract infection: a mystery in search of better model systems","volume":"11","author":"Murray","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2025020223513567300_dkae424-B36","doi-asserted-by":"publisher","first-page":"e75798","DOI":"10.7554\/eLife.75798","article-title":"Inhibiting host-protein deposition on urinary catheters reduces associated urinary tract infections","volume":"11","author":"Andersen","year":"2022","journal-title":"Elife"},{"key":"2025020223513567300_dkae424-B37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrd1008","article-title":"Understanding biofilm resistance to antibacterial agents","volume":"2","author":"Davies","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2025020223513567300_dkae424-B38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12575-019-0106-0","article-title":"MBEC versus MBIC: the lack of differentiation between biofilm reducing and inhibitory effects as a current problem in biofilm methodology","volume":"21","author":"Thieme","year":"2019","journal-title":"Biol Proced Online"},{"key":"2025020223513567300_dkae424-B39","doi-asserted-by":"publisher","first-page":"1128132","DOI":"10.3389\/fcimb.2023.1128132","article-title":"An immunoresponsive three-dimensional urine-tolerant human urothelial model to study urinary tract infection","volume":"13","author":"Jafari","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"2025020223513567300_dkae424-B40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/1040841X.2023.2167593","article-title":"A comprehensive status update on modification of foley catheter to combat catheter-associated urinary tract infections and microbial biofilms","volume":"50","author":"Chadha","year":"2024","journal-title":"Crit Rev Microbiol"},{"key":"2025020223513567300_dkae424-B41","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.chom.2016.09.004","article-title":"Enterococcal metabolite cues facilitate interspecies niche modulation and polymicrobial infection","volume":"20","author":"Keogh","year":"2016","journal-title":"Cell Host Microbe"},{"key":"2025020223513567300_dkae424-B42","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/pathogens9100835","article-title":"Enterococcus faecalis polymicrobial interactions facilitate biofilm formation, antibiotic recalcitrance, and persistent colonization of the catheterized urinary tract","volume":"9","author":"Gaston","year":"2020","journal-title":"Pathogens"},{"key":"2025020223513567300_dkae424-B43","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00652-20","article-title":"Polymicrobial interactions in the urinary tract: is the enemy of my enemy my friend?","author":"Gaston","year":"2021;","journal-title":"Infect Immun"},{"key":"2025020223513567300_dkae424-B44","author":"Bonkat"},{"key":"2025020223513567300_dkae424-B45","doi-asserted-by":"publisher","first-page":"e144775","DOI":"10.1172\/jci.insight.144775","article-title":"Prospective assessment of catheter-associated bacteriuria clinical presentation, epidemiology, and colonization dynamics in nursing home residents","volume":"6","author":"Armbruster","year":"2021","journal-title":"JCI Insight"},{"key":"2025020223513567300_dkae424-B46","doi-asserted-by":"publisher","first-page":"e00084-16","DOI":"10.1128\/CMR.00084-16","article-title":"Options and limitations in clinical investigation of bacterial biofilms","volume":"31","author":"Magana","year":"2018","journal-title":"Clin Microbiol Rev"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/2\/413\/60922231\/dkae424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/2\/413\/60922231\/dkae424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T23:52:14Z","timestamp":1738540334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/2\/413\/7913994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,29]]},"published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae424","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,11,29]]}}}